Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy

Anastasilakis, Athanasios D.; Koulaxis, Dimitrios; Kefala, Nikoleta; Polyzos, Stergios A.; Upadhyay, Jagriti; Pagkalidou, Eirini; Economou, Fotios; Anastasilakis, Chrysostomos D.; Mantzoros, Christos S.

doi:10.1016/j.metabol.2017.05.002

Cited by 58 publications

(49 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can be explained by that these studies include obesity and metabolic syndrome patients who had a higher irisin level (a state of resistance to irisin signaling) Xiong et al 2015. indicated that FNDC5/irisin plays a beneficial role in attenuating hypertension via inhibiting sympathetic activation in obesity.The present study showed marked reduction in LVEF in both AMI & HF patients compared to control group & this decrease was prominent in HF group versus MI group.This was in agreement withAther 2008 & Matsuo et al 2015 In addition, the positive correlation between irisin and LVEF in both groups of patients was in the same line with that reported byGloria- Bottini et al 2016& Anastasilakis et al 2017 who observed correlation between decreased circulating irisin levels in MI patients, LVEF and the severity of coronary arteries stenosis. However,Silvestrini et al 2019 reported no significant correlation between irisin and LVEF in heart failure with preserved or reduced ejection fraction.…”

supporting

confidence: 91%

“…However, some authors hypothesized that lower irisin in MI may be the cause rather than the result of diminished coronary blood flow (Anastasilakis et al 2017) (the irisin precursor) were markedly reduced in HF rats (Strassburg et al 2005).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the prominent negative correlations between irisin level and cardiac biomarkers (troponin-I & CK-MB) after MI and HF were in agreement with Kuloglu et al 2014. Thus, serum irisin level could serve as a marker for MI with accuracy similar to CK-MB and it is not inferior to CK-MB in predicting MI (Anastasilakis et al 2017).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Serum irisin level in myocardial infarction patients with or without heart failure

El-Mottaleb

Galal

Maghraby

et al. 2019

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

This study aimed to assess serum irisin level in myocardial infarction (MI) with or without heart failure (HF) and the possible relation between irisin and cardiac markers, TNF-α and lipid profile. 86 subjects were included (33 patients had MI, 33 patients had MI with HF and 20 controls). Body Mass Index (BMI), waist/hip ratio (WHR), systolic and diastolic blood pressure (SBP and DBP), heart rate, left ventricular ejection fraction (LVEF) were measured. Blood samples were withdrawn on admission for measuring irisin, cardiac markers, TNF-α, total cholesterol (TC), triglycerides (TGs), low density lipoprotein-cholesterol concentration (LDL-C) and high-density lipoprotein-cholesterol concentration (HDL-C). Patients with MI and HF had reduced serum irisin, LVEF and HDL-C and higher levels of BMI, WHR, SBP, DBP, troponin-I, CK-MB, TNF-α, TC, TGs and LDL-C compared to control. Negative correlations were observed between irisin and BMI, WHR, SBP, DBP, troponin-I, CK-MB, TNF-α, TC, TGs and LDL-C. However, positive association was noticed between irisin and LVEF and HDL-C. Irisin might be a useful biomarker in diagnosis of MI with or without HF. It could have antiinflammatory and hypolipidemic effects. Further studies are needed to elucidate the role of irisin as a promising prophylactic or therapeutic agent in cardiovascular diseases.

show abstract

supporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum irisin level in myocardial infarction patients with or without heart failure

El-Mottaleb

Galal

Maghraby

et al. 2019

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…As a newly identified hormone, the major function of irisin is regulating glucose/lipid metabolism and mitochondrial function . However, as research continues, it has been shown that irisin also benefits type 2 diabetes, ageing and some cardiovascular diseases . In addition, many studies have shown that irisin can facilitate AMPK activation to further regulate energy metabolism .…”

Section: Introductionmentioning

confidence: 99%

“…14,15 However, as research continues, it has been shown that irisin also benefits type 2 diabetes, ageing and some cardiovascular diseases. [16][17][18] In addition, many studies have shown that irisin can facilitate AMPK activation to further regulate energy metabolism. 13 A recent study indicated that irisin restrains bone loss by binding to the αv class of integrins in osteocytes.…”

mentioning

confidence: 99%

Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin αVβ5 receptor

Zhang

Ren

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Disruption of the gut barrier results in severe clinical outcomes with no specific treatment. Metabolic disorders and destruction of enterocytes play key roles in gut barrier dysfunction. Irisin is a newly identified exercise hormone that regulates energy metabolism. However, the effect of irisin on gut barrier function remains unknown. The therapeutic effect of irisin on gut barrier dysfunction was evaluated in gut ischemia reperfusion (IR). The direct effect of irisin on gut barrier function was studied in Caco‐2 cells. Here, we discovered that serum and gut irisin levels were decreased during gut IR and that treatment with exogenous irisin restored gut barrier function after gut IR in mice. Meanwhile, irisin decreased oxidative stress, calcium influx and endoplasmic reticulum (ER) stress after gut IR. Moreover, irisin protected mitochondrial function and reduced enterocyte apoptosis. The neutralizing antibody against irisin significantly aggravated gut injury, oxidative stress and enterocyte apoptosis after gut IR. Further studies revealed that irisin activated the AMPK‐UCP 2 pathway via binding to the integrin αVβ5 receptor. Inhibition of integrin αVβ5, AMPK or UCP 2 abolished the protective role of irisin in gut barrier function. In conclusion, exogenous irisin restores gut barrier function after gut IR via the integrin αVβ5‐AMPK‐UCP 2 pathway.

show abstract

Irisin Promotes Cardiac Homing of Intravenously Delivered MSCs and Protects against Ischemic Heart Injury

et al. 2022

View full text Add to dashboard Cite

Few intravenously administered mesenchymal stromal cells (MSCs) engraft to the injured myocardium, thereby limiting their therapeutic efficacy for the treatment of ischemic heart injury. Here, it is found that irisin pretreatment increases the cardiac homing of adipose tissue‐derived MSCs (ADSCs) administered by single and multiple intravenous injections to mice with MI/R by more than fivefold, which subsequently increases their antiapoptotic, proangiogenic, and antifibrotic effects in rats and mice that underwent MI/R. RNA sequencing, Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway analysis, and loss‐of‐function studies identified CSF2RB as a cytokine receptor that facilitates the chemotaxis of irisin‐treated ADSCs in the presence of CSF2, a chemokine that is significantly upregulated in the ischemic heart. Cardiac‐specific CSF2 knockdown blocked the cardiac homing and cardioprotection abilities of intravenously injected irisin‐treated ADSCs in mice subjected to MI/R. Moreover, irisin pretreatment reduced the apoptosis of hydrogen peroxide‐induced ADSCs and increased the paracrine proangiogenic effect of ADSCs. ERK1/2‐SOD2, and ERK1/2‐ANGPTL4 are responsible for the antiapoptotic and paracrine angiogenic effects of irisin‐treated ADSCs, respectively. Integrin αV/β5 is identified as the irisin receptor in ADSCs. These results provide compelling evidence that irisin pretreatment can be an effective means to optimize intravenously delivered MSCs as therapy for ischemic heart injury.

show abstract

Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy

Cited by 58 publications

References 33 publications

Serum irisin level in myocardial infarction patients with or without heart failure

Serum irisin level in myocardial infarction patients with or without heart failure

Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin αVβ5 receptor

Irisin Promotes Cardiac Homing of Intravenously Delivered MSCs and Protects against Ischemic Heart Injury

Contact Info

Product

Resources

About